eSignal IPO Calendar

Week of Expected Pricing	Pending
Company Name	Versartis, Inc
Proposed Ticker	N/A
CUSIP	92529L102
Business Description	An endocrine-focused biopharmaceutical company initially developing our novel long-acting recombinant human growth hormone, VRS-317, for growth hormone deficiency, or GHD, an orphan disease.
Lead Underwriter	Citigroup Global Markets Inc Morgan Stanley & Co. LLC.
Co-Managers	Canaccord Genuity Inc Cowen and Company, LLC.
Initial Shares	N/A
Revised Initial Shares	N/A
Initial Price	N/A
Revised Price	N/A
Final Price	N/A
Final Ticker	N/A